Ospemifene interactions

Food & lifestyle

• high-fat foods

  Moderate

  Absorption

  Food significantly enhances the oral bioavailability of ospemifene. In a cross-study comparison, administration of a single 60 mg dose of ospemifene with a high-fat/high-calorie meal (860 kcal) in postmenopausal women increased ospemifene peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.3- and 1.7-fold, respectively, compared to administration under fasted condition.

  What to do: Ospemifene should be taken once daily with food.

  1 source

  1. "Product Information. Osphena (ospemifene)." Shionogi USA Inc (2013):

Conditions

Conditions in which Ospemifene needs care, as documented in this source.

• Breast Neoplasms

  Major

  Ospemifene has not been adequately studied in women with breast cancer, therefore should not be used in women with known, suspected or with a history of breast cancer. Additionally, ospemifene is contraindicated in the presence of any known or suspected estrogen-dependent neoplasia.

  1 source

  1. "Product Information. Osphena (ospemifene)." Shionogi USA Inc (2013):

• Cardiovascular disease

  Major

  There is a reported increase of stroke and deep vein thrombosis (DVT) in postmenopausal women receiving oral conjugated estrogens. Ospemifene should be prescribed for the shortest duration consistent with treatment goals, weighting risks and benefits for each woman. Ospemifene is contraindicated in women with active DVT, pulmonary embolism, active arterial thromboembolic disease (such as stroke or myocardial infarctions), or a history of any of these conditions. Other risk factors for cardiovascular disorders and/or venous thromboembolism such as hypertension, diabetes, smoking, hypercholesterolemia, obesity, lupus erythematosus (in personal or family history), should be evaluated and managed appropriately.

  1 source

  1. "Product Information. Osphena (ospemifene)." Shionogi USA Inc (2013):

• Liver Failure

  Major

  Ospemifene should not be used in women with severe hepatic impairment, as the pharmacokinetics have not been studied in these patients. No clinically important differences were observed in women with mild to moderate hepatic impairment when compared to healthy women, therefore no dose adjustment is needed in these patients.

  1 source

  1. "Product Information. Osphena (ospemifene)." Shionogi USA Inc (2013):

• Uterine Hemorrhage

  Major

  The use of ospemifene is contraindicated in women with any undiagnosed abnormal genital bleeding. There is an increased risk of endometrial hyperplasia and endometrial cancer in patients using estrogens. Adequate diagnostic measures should be undertaken to rule out malignancy in any postmenopausal woman with undiagnosed persistent or recurring abnormal genital bleeding.

  1 source

  1. "Product Information. Osphena (ospemifene)." Shionogi USA Inc (2013):

Therapeutic duplication

Drug classes that overlap with Ospemifene, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

• selective estrogen receptor modu

  The recommended maximum number of medicines in the 'selective estrogen receptor modulators' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'selective estrogen receptor modulators' category.

  Example product in the source data (US market): Duavee